Search Results 11-20 of 16575 for B cell lymphomas
In a study of axicabtagene ciloleucel (axi-cel) CAR-T cell therapy for relapsed or refractory aggressive B-cell lymphoma, 30-day responses were comparable ...
CAR -T cell therapy might be an option for certain types of B-cell non-Hodgkin's lymphoma that haven't responded to other treatments. Bone marrow transplant.
— Feb. 18, 2014 — Newly-diagnosed patients with diffuse large B cell lymphoma (DLBCL) who do not experience any cancer-related outcome events for two years ...
— The targeted therapy everolimus may be safely combined with R-CHOP for new, untreated diffuse large B-cell lymphoma according to the results of a pilot study ...
B-cell lymphomas are a heterogeneous group of neoplasms that arise from lymphocytes and produce tumors in the lymph nodes, lymphatic organs and extranodal ...
A Study to Determine the Outcomes of Patients With Localized B Cell Lymphoblastic Lymphoma (B-LLy) When Treated With Standard Risk B-ALL Therapy ... - B-ALL ...
Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy · Overview · Participation ...
T-cell/histiocyte-rich large B cell lymphoma. Large B-cell lymphoma with ... FDG-nonavid lymphomas: Measurable disease with CT (or MRI) scan with ...
It targets the B-cell lymphoma 2 (BCL-2) protein, which supports cancer cell growth and is overexpressed in many patients with mantle cell lymphoma. Venetoclax ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Make your tax-deductible gift and be a part of the cutting-edge research and care that's changing medicine.